Ornella Cutaia

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Oncology · 2013 · 354 citations

Medicine, Oncology, Pharmacology +11

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Respiratory Medicine · 2015 · 204 citations

Medicine, Oncology, Pharmacology +11

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

Riccardo Danielli, Roberto Patuzzo, Anna Maria Di Giacomo et al. · Cancer Immunology Immunotherapy · 2015 · 179 citations · Full text

Medicine, Immunology, Oncology +15

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Anna Maria Di Giacomo, Luana Calabrò, Riccardo Danielli et al. · Cancer Immunology Immunotherapy · 2013 · 135 citations · Full text

Medicine, Immunology, Oncology +17

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Anna Maria Di Giacomo, Alessia Covre, Francesca Finotello et al. · Clinical Cancer Research · 2019 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17